CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: August 7, 2007
Result type: Reports
Project Number: S0106
Product Line: Common Drug Review

Generic Name: Delta-9-tetrahydrocannabinol/cannabidiol

Brand Name: Sativex

Manufacturer: GW Pharma Ltd.

Indications: Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids)

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: February 20, 2008

Recommendation Type: Do not list